Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital ...

Markets worldwide defied expectations in 2024 led by the dominating performance of mega-cap technology stocks known as the ...

Private equity fundraising struggled in 2024, with total capital raised declining for the third consecutive year. Read more ...

The Carlyle Group and SK Capital Partners have agreed to acquire bluebird bio, Inc, a Somerville, Massachusetts-based gene therapy firm, in a take-private deal. According to terms of the agreement, ...

Interim CEO Brent Shafer said the medical products maker is ready to begin a new era after several years of “heavy lifting” ...

The pioneering gene therapy developer will be acquired by investment firms Carlyle Group and SK Capital for a fraction of ...

Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.

Sedgwick, a provider of claims management, loss adjusting and technology-enabled business solutions, has agreed to acquire Thoma Bravo -based Bottomline’s legal spend management (LSM) division. No ...

They invest in public stocks and bonds, and their clients are increasingly sensitive to costs. Their most popular products these days are passive index trackers with razor-thin fees, often just a few ...

Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...

There is a catch. If the private equity firms can boost sales of bluebird’s three gene therapies to $600 million—over any ...